PCN13 Quality-of-Life (QOL) Results from the Phase 3 Rainbow-ASIA Study of Ramucirumab PLUS paclitaxel (RAM/PTX) Versus Placebo PLUS paclitaxel (PBO/PTX) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (AGC)
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.105
https://www.valueinhealthjournal.com/article/S1098-3015(21)00322-3/fulltext
Title :
PCN13 Quality-of-Life (QOL) Results from the Phase 3 Rainbow-ASIA Study of Ramucirumab PLUS paclitaxel (RAM/PTX) Versus Placebo PLUS paclitaxel (PBO/PTX) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (AGC)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00322-3&doi=10.1016/j.jval.2021.04.105
First page :
Section Title :
Open access? :
No
Section Order :
10548